Affordable Access

deepdyve-link
Publisher Website

IGF2 and cancer.

Authors
  • Livingstone, Callum
Type
Published Article
Journal
Endocrine Related Cancer
Publisher
Bioscientifica
Publication Date
Dec 01, 2013
Volume
20
Issue
6
Identifiers
DOI: 10.1530/ERC-13-0231
PMID: 24080445
Source
Medline
Keywords
License
Unknown

Abstract

Insulin-like growth factor 2 (IGF2) is a 7.5  kDa mitogenic peptide hormone expressed by liver and many other tissues. It is three times more abundant in serum than IGF1, but our understanding of its physiological and pathological roles has lagged behind that of IGF1. Expression of the IGF2 gene is strictly regulated. Over-expression occurs in many cancers and is associated with a poor prognosis. Elevated serum IGF2 is also associated with increased risk of developing various cancers including colorectal, breast, prostate and lung. There is established clinical utility for IGF2 measurement in the diagnosis of non-islet cell tumour hypoglycaemia, a condition characterised by a molar IGF2:IGF1 ratio >10. Recent advances in understanding of the pathophysiology of IGF2 in cancer have suggested much novel clinical utility for its measurement. Measurement of IGF2 in blood and genetic and epigenetic tests of the IGF2 gene may help assess cancer risk and prognosis. Further studies will determine whether these tests enter clinical practice. New therapeutic approaches are being developed to target IGF2 action. This review provides a clinical perspective on IGF2 and an update on recent research findings.

Report this publication

Statistics

Seen <100 times